Ophthalmic Composition with Polyvinylpyrrolidone for JAK Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eye diseases such as dry eye syndrome, uveitis, and glaucoma are inadequate in effectively addressing the underlying cytokine signaling pathways, particularly those involving JAK kinases, leading to suboptimal therapeutic outcomes.
Innovation Solution
A composition for ophthalmic administration comprising 5% to 15% w/v polyvinylpyrrolidone with a molecular weight of 40,000 to 60,000, along with compounds I and/or II, or their pharmaceutically acceptable salts, solvates, or N-oxides, which selectively inhibit JAK kinases, thereby targeting cytokine signaling pathways to treat eye diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for eye diseases are used, then conventional therapy is provided, but therapeutic outcomes are suboptimal due to inadequate addressing of cytokine signaling pathways
Solution Approach 1:
The patent changes the pharmacological parameter by introducing JAK kinase inhibitors (compounds I and II) that specifically target cytokine signaling pathways. This parameter change transforms the treatment mechanism from conventional non-specific therapy to targeted inhibition of JAK kinases, thereby improving therapeutic outcomes for eye diseases mediated by these pathways.
Solution Approach 2:
The patent uses polyvinylpyrrolidone as an intermediary substance to enhance the delivery and stability of JAK kinase inhibitors. This intermediary polymer improves the solubility and bioavailability of the active compounds, enabling effective targeting of cytokine signaling pathways while achieving reliable therapeutic outcomes.
2Stability of the object's composition
If polyvinylpyrrolidone with higher molecular weight is used, then solubility and stability of active compounds improve, but viscosity increases affecting ease of administration
Solution Approach 1:
The patent optimizes the molecular weight parameter of polyvinylpyrrolidone to fall within the range of 40,000 to 60,000. This parameter optimization balances the competing requirements: molecular weight is sufficiently high to provide adequate solubility and stability enhancement for JAK kinase inhibitors, yet low enough to maintain acceptable viscosity for ophthalmic administration.
Solution Approach 2:
The patent applies local quality by using polyvinylpyrrolidone specifically in the ophthalmic composition formulation rather than throughout the entire drug delivery system. This localized application of the polymer provides stability and solubility benefits precisely where needed (in the eye drop formulation) without unnecessarily increasing viscosity elsewhere in the administration system.
3Reliability
If concentration of JAK kinase inhibitors is increased to improve therapeutic efficacy, then treatment effectiveness improves, but solubility limitations are reached
Solution Approach 1:
The patent employs polyvinylpyrrolidone as a solubility-enhancing intermediary that forms inclusion complexes or micellar structures with JAK kinase inhibitors. This intermediary mechanism allows significantly higher concentrations of the active compounds to be dissolved in the ophthalmic formulation, thereby achieving improved therapeutic efficacy without being constrained by the inherent solubility limitations of the inhibitors.
Solution Approach 2:
The patent creates a composite ophthalmic composition combining polyvinylpyrrolidone with JAK kinase inhibitors. This composite material system leverages the solubility-enhancing properties of the polymer matrix to accommodate high concentrations of the therapeutic agents, resolving the contradiction between achieving high therapeutic efficacy and maintaining adequate solubility.
Data Source
Figure 1~2
AI summary
Disclosed herein are embodiments of a composition useful for treating and/or preventing dry eye disorders. The disclosed composition comprises components that maintain the composition' s chemical and/or physical properties thereby providing a composition suitable for use.